Other Affiliations
and Conflict Disclosure
DirectorAnnual Reviews, Global Coalition for Adaptive Research (GCAR), n-Lorem Foundation, Vesalius TherapeuticsAdvisor toAACR Oncology Development Fund, AIF Global, Apricity Health, Aracari Bio, Aurora Therapeutics, AUTS2 Research Collaborative, Cancer Focus Fund, Ellison Medical Institute, Health at Scale, Khora Therapeutics, Ride Therapeutics, Roivant Social Ventures, Sakura Health, Tango, Swiss Finance Institute, Thalēs, Think Therapeutics, xCuresCo-founderQLS TechnologiesCo-founder and AdvisorGondola Bio, Rutherford Energy VenturesCo-founder and ChairmanENRAPT, QLS AdvisorsCo-founder and DirectorBridgeBio Pharma, Arlyn (formerly Quantile Health), TechTransferase, Uncommon CuresPersonal investments inACISM, Apricity Health, Aracari Bio, Arlyn (formerly Quantile Health), BillionToOne, BridgeBio Pharma, Fidelity Select Biotech Fund, Khora Therapeutics, Ladder Tx, LS Polaris Innovation Fund, Macrocosm LLC, Medallion, MPM Capital Fund, Nautilus Biotech, Nurture Genomics, Peer Collective, Polaris Innovation Fund II, Proactive Labs, PsiThera, Ride Therapeutics, Sakura Health, Stratus Therapeutics, SURGE Therapeutics, Uncommon Cures, Waypoint Bio
During the most recent six-year period, Lo has received speaking/consulting fees, honoraria, or other forms of compensation from: AbCellera, AlphaSimplex, Annual Reviews, Apricity Health, Aracari Bio, Arlyn (formerly Quantile Health), Atomwise, BridgeBio, CME, Enable Medicines, JOIM, Lazard, MIT, New Frontier Advisors, Oppenheimer, Princeton University Press, Q Group, QLS Advisors, Roivant Sciences, Rutherford Energy Ventures, Saliogen, Stern Speakers, Swiss Finance Institute, Think Tx, Vesalius, and WW Norton. In addition, the MIT Laboratory for Financial Engineering (LFE), for which Lo serves as director, has received funding support from the Critical Path Institute, J.P. Morgan Asset & Wealth Management, NextGen Industry Group, and Schmidt Futures. [Last updated: 29 October 2026]
